Nampt-IN-22
Nampt-IN-22 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-22 blocks the NAD+ salvage synthesis pathway by inhibiting nicotinamide phosphoribosyltransferase (NAMPT). Its tertiary alcohol forms hydrogen bonds with His191 of NAMPT and enhances lysosomal stability via intramolecular hydrogen bonds. As an ADC payload, Nampt-IN-22 exhibits low nanomolar cytotoxicity against tumor cells after conjugation to an anti-CD30 antibody, prolongs survival in a disseminated L540 Hodgkin lymphoma mouse model, and suppresses subcutaneous tumor growth. Nampt-IN-22 can be used in studies related to Hodgkin lymphoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3087291-80-0
- Fòrmula: C23H29N7O2
- Peso molecular:435.52
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Nampt-IN-22 (compound 3) (24 h) exhibits partial resistance to acid-induced hydration into inactive guanylurea metabolites, with only 23% conversion observed after treatment at pH < 2 and 37°C[1].
Nampt-IN-22 (72 h) produces no detectable levels of the inactive guanidino urea metabolite after incubation with human liver lysosomal extracts at 37°C, indicating its resistance to enzyme-driven lysosomal conversion[1].
Free Nampt-IN-22 (0.0001-10 µM; 96 h) inhibits the viability of CD30-positive human Hodgkin's lymphoma L540 cells, with an IC50 of 0.1395 µM, and achieves complete cell killing at high concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nampt-IN-22 (conjugated to anti-CD30 antibody, DAR10) (administered intravenously once weekly for 4 weeks) achieves significant tumor inhibition in CB-17 SCID mice subcutaneously inoculated with Hodgkin lymphoma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 3087291-80-0
-
Peso molecular 435.52
-
Fòrmula C23H29N7O2
-
SMILES
N#C/N=C(NC1=CC=CN=C1)\NCCCCC2(O)CCN(C(C3=CC=CC(N)=C3)=O)CC2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nampt-IN-22 Related Classifications
HY-187336 Related Classifications
Powered by Bioz
- Nampt-IN-22
- 3087291-80-0
- NAMPT
- CD30+ hematological cancer cells
- nicotinamide phosphoribosyltransferase
- disseminated hematological cancer mouse xenograft models
- His191
- L540 cells
- NXG mice
- hodgkin lymphoma
- subcutaneous solid hematological cancer mouse xenograft models
- antibody-drug conjugate
- Inhibitor
- inhibitor
- inhibit